Posted by Michael Wonder on 30 Jan 2022
FDA approves Genentech’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
28 January 2022 - Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive wet age-related macular degeneration and diabetic macular oedema.
Genentech today announced that the U.S. FDA has approved Vabysmo (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular oedema.
